MC
JAZZ icon

Muhlenkamp & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Muhlenkamp & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,460
Closed -$8.33M – 37
2020
Q4 		$8.33M Buy
50,460
+213
+0.4% +$31.7K 3.35% 16
2020
Q3 		$7.17M Buy
50,247
+484
+1% +$60K 3.71% 15
2020
Q2 		$5.49M Buy
+49,763
New +$5.5M 2.94% 18
2019
Q4 		$7.41M Buy
49,626
+13,384
+37% +$1.82M 3.24% 14
2019
Q3 		$4.64M Buy
36,242
+39
+0.1% +$5.23K 2.26% 21
2019
Q2 		$5.16M Sell
36,203
-121
-0.3% -$16.3K 2.51% 21
2019
Q1 		$5.19M Buy
+36,324
New +$4.74M 2.46% 20
2018
Q3 		$6.22M Sell
36,971
-184
-0.5% -$31.6K 2.66% 20
2018
Q2 		$6.4M Buy
+37,155
New +$6.07M 2.44% 20

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Muhlenkamp & Co's JAZZ Position: Q1 2021 in Review

Muhlenkamp & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2021, closing a stake of 50,460 shares — an estimated $8.33M sold.

Muhlenkamp & Co first reported a position in JAZZ in Q2 2018 and held it in 9 quarters. The position peaked at $8.33M in Q4 2020. 441 funds tracked by Wall St. Rank hold JAZZ as of Q1 2021.

  • Muhlenkamp & Co reported no remaining Jazz Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Muhlenkamp & Co sold 50,460 Jazz Pharmaceuticals shares in Q1 2021, an estimated $8.33M.
  • Muhlenkamp & Co first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 9 quarters.
  • Muhlenkamp & Co's Jazz Pharmaceuticals position peaked at $8.33M in Q4 2020.
  • 441 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2021.

Based on Muhlenkamp & Co's 13F filing for Q1 2021, filed 18 Aug 2021.